Plain-English summaries of weight-loss medicine decisions and trial results, newest first. Every item links to the label, regulator page, company announcement or journal paper it came from.
The interim peptide access policy. A draft was sent to the White House budget office on October 14, 2026. It has not been issued and its contents are not public. See the Peptide policy tracker.
FDA action on the peptides the advisory committee recommended. The committee voted in July 2026 to recommend six peptides for the 503A bulks list. The Atlas has not found an FDA decision on adding them. See the Peptide policy tracker.
A second advisory committee meeting on peptides. Expected before the end of February 2027 for GHK-Cu, LL-37, Dihexa, Melanotan II and PEG-MGF. No date is set.
An FDA decision on CagriSema. Novo Nordisk filed CagriSema in December 2025. The Atlas has not confirmed an approval, and no decision date has been given.
A retatrutide filing. Lilly says it plans to submit retatrutide to the FDA in the first quarter of 2027. It is not approved anywhere.
How this page works
The Atlas picks items that change what is approved, what is available, how a medicine is regulated, or what a published trial found. It does not cover stock prices, rumors or opinion pieces.
Company announcements are used to say what a company announced. They are not proof of how well a medicine works until the full results are published, and each item says which kind of source it uses.
The Atlas checks its sources every weekday and adds an item only after it has been reviewed. The dates on each item show when the event happened.
| Trial results
Retatrutide lowered sleep apnea severity more than placebo in two phase 3 trials
The New England Journal of Medicine published two placebo-controlled trials of once-weekly retatrutide in adults with moderate-to-severe obstructive sleep apnea and a body mass index of at least 27. TRIUMPH-1-OSA had 243 people without type 2 diabetes. TRIUMPH-2-OSA had 448 people with type 2 diabetes. At 80 weeks, the average number of breathing interruptions per hour of sleep (the AHI) fell by 9.9 on placebo in the first trial and by 22.9, 34.3 and 31.7 on the 4 mg, 9 mg and 12 mg doses. In the second trial it fell by 10.3 on placebo and by 19.2, 24.7 and 25.4.
Average weight loss was 12.5% to 22.2% in the first trial and 12.1% to 18.5% in the second, versus 4.8% and 5.6% on placebo. The most common side effects were stomach and gut problems.
Worth knowing: The AHI counts breathing events. The abstract does not say how many people no longer had sleep apnea afterward. Lilly paid for the trials, and retatrutide is not approved for any use. Lilly has said it plans to file with the FDA in the first quarter of 2027.
HHS sends a draft peptide "interim access policy" to the White House for review
A law-firm review and a STAT report say a draft interim policy for compounding certain peptides, including BPC-157, was sent to the White House Office of Management and Budget on October 14, 2026. Sources familiar with the plan told STAT it would let pharmacies compound some peptides for a time without FDA enforcement.
It has not been issued, and its contents are not public.
Worth knowing: This would not be an FDA approval of any peptide, and FDA staff recommended against adding the peptides reviewed in July.
FDA updates its warning page on unapproved GLP-1 drugs
The FDA refreshed its page on unapproved GLP-1 drugs used for weight loss. It says compounded semaglutide and tirzepatide are not FDA-approved and are not reviewed for safety, effectiveness or quality before sale. As of May 31, 2026 it had 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide, which it says are likely underreported.
Worth knowing: The page also covers dosing errors, counterfeit products and products sold "for research" but marketed for human use. The Atlas explains the differences on its compounded versus brand-name page.
Petrelintide phase 2 results published: about 8% to 10% weight loss at 28 weeks
A phase 2 trial of petrelintide, an investigational once-weekly amylin medicine, was published in The Lancet Diabetes and Endocrinology. In 485 adults without diabetes, average weight change at 28 weeks was between -7.9% and -9.8% across five doses, compared with -1.7% on placebo. Weight kept falling to week 42, by up to 10.7%.
Nausea was the most common side effect, at 20% versus 6% on placebo. The trial was funded by Zealand Pharma.
Worth knowing: It is a mid-stage trial with a short follow-up. Petrelintide is not approved anywhere, and larger phase 3 trials are needed.
Appeals court reportedly upholds FDA decisions that GLP-1 shortages ended
A law-firm summary dated September 10, 2026 reports that the Fifth Circuit upheld the FDA decisions that the semaglutide and tirzepatide shortages were over. The summary says compounders can no longer rely on the shortage exception for large-scale copies, while patient-specific compounding can continue when legal requirements are met.
Worth knowing: The Atlas has not read the court decision itself, which is unpublished, so treat this as a secondary report.
FDA advisory committee recommends six of seven peptides for the compounding list
The FDA Pharmacy Compounding Advisory Committee met July 23 and 24, 2026. It voted to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax for the 503A bulks list, and voted against emideltide (DSIP). The closest recommended votes were 7 to 5 for MOTS-c and 8 to 6 for BPC-157, KPV and TB-500.
Worth knowing: The votes are advice, not a rule, and not an approval. Reports say FDA staff recommended against all seven.
Lilly reports two more retatrutide phase 3 trials and plans a 2027 filing
Lilly announced results from TRIUMPH-2 (people with type 2 diabetes) and TRIUMPH-3 (severe obesity with cardiovascular disease). At 80 weeks, average weight loss was up to 20.8% in TRIUMPH-2 and up to 22.6% in TRIUMPH-3, versus 4.0% and 3.2% on placebo. Stopping because of side effects was 3.8% to 13.5% on retatrutide versus 4.8% to 4.9% on placebo.
Lilly says it plans to submit retatrutide to the FDA in the first quarter of 2027.
Worth knowing: These are company-announced results. Retatrutide is investigational and not approved or available as a medicine anywhere.
Medicare bridge program lets some people with Part D get weight-loss medicines for $50 a month
NPR reported a temporary Medicare program running from July 1, 2026 through December 31, 2027. People in a Part D plan who meet the criteria can get Wegovy, the Zepbound KwikPen or Foundayo for a flat $50 a month. The criteria are a BMI of 35 or higher, or 27 or higher with a condition such as heart disease or prediabetes, and prior authorization is required.
Worth knowing: Rules like this change. Check Medicare.gov and your own plan.
FDA approves Foundayo (orforglipron), a once-daily GLP-1 pill for weight loss
The FDA approved orforglipron as Foundayo for adults with obesity, or overweight with a related condition. It is a daily tablet taken with or without food. In the 72-week ATTAIN-1 trial, people on the highest dose who stayed on treatment lost an average of 12.4% of body weight, versus 0.9% on placebo. Across everyone randomized, the figures were 11.1% versus 2.1%.
Lilly said self-pay prices start at $149 a month for the lowest dose, with other prices depending on insurance.
Worth knowing: Prices and coverage change often. The label lists the warnings, including pancreatitis, gallbladder problems and dehydration.
The FDA approved a 7.2 mg weekly dose of semaglutide for adults who have tolerated the 2.4 mg dose for at least 4 weeks and for whom more weight reduction is clinically indicated. In the 72-week STEP UP trial of 1,407 adults without diabetes, 89% on 7.2 mg lost at least 5% of their weight versus 38% on placebo.
Skin sensation changes, such as tingling or sensitivity, occurred in 22% on the higher dose versus 6% on 2.4 mg and 0.3% on placebo.
Worth knowing: The current Wegovy label describes the 7.2 mg option. Whether it suits someone is a decision for them and their prescriber.
FDA announces warning letters to 30 telehealth firms over compounded GLP-1 marketing
Pharmaceutical Commerce reported that the FDA sent warning letters to 30 telehealth firms over marketing that suggested compounded GLP-1 products were the same as approved ones.
Worth knowing: It shows how closely regulators are watching how compounded products are described. The Atlas does not rate or list any telehealth firm.
Novo Nordisk submitted CagriSema, a weekly combination of semaglutide and cagrilintide, for FDA approval for weight management. The filing is based on the REDEFINE 1 trial, in which people lost 20.4% of body weight versus 3.0% on placebo over 68 weeks counting everyone randomized, and 22.7% versus 2.3% for those who stayed on treatment.
Novo said the FDA is expected to review the application in 2026 and did not give a decision date.
Worth knowing: As of the Atlas check, the Atlas has not confirmed an FDA approval of CagriSema. It is not an approved product.
Not medical advice. News items describe what was announced or published. They do not say whether a medicine is right for you. A licensed clinician who knows your history does.